about
Endothelial cell control of thrombosisSelecting Patients for Intra-Arterial Therapy in the Context of a Clinical Trial for Neuroprotection.Tempol, an intracellular antioxidant, inhibits tissue factor expression, attenuates dendritic cell function, and is partially protective in a murine model of cerebral malaria.Inflammation-associated activation of coagulation and immune regulation by the protein C pathway.A hereditary bleeding disorder resulting from a premature stop codon in thrombomodulin (p.Cys537Stop)ELISA-Based Detection System for Protein S K196E Mutation, a Genetic Risk Factor for Venous Thromboembolism.Activated protein C upregulates ovarian cancer cell migration and promotes unclottability of the cancer cell microenvironment.Exacerbated venous thromboembolism in mice carrying a protein S K196E mutationHaplotypes of the endothelial protein C receptor (EPCR) gene are not associated with severe malaria in Tanzania.Activated protein C ameliorates diabetic nephropathy by epigenetically inhibiting the redox enzyme p66ShcActivated protein C promotes neuroprotection: mechanisms and translation to the clinic.An activated protein C analog stimulates neuronal production by human neural progenitor cells via a PAR1-PAR3-S1PR1-Akt pathway.Activated protein C analog promotes neurogenesis and improves neurological outcome after focal ischemic stroke in mice via protease activated receptor 1Altered fibrinolysis in autosomal dominant thrombomodulin-associated coagulopathy.Protein C and acute inflammation: a clinical and biological perspective.The role of biochemical risk factors in the etiology of AIS in children and adults.Present and future of anticoagulant therapy using antithrombin and thrombomodulin for sepsis-associated disseminated intravascular coagulation: a perspective from Japan.Novel insights into the regulation of coagulation by factor V isoforms, tissue factor pathway inhibitorα, and protein S.2016 Scientific Sessions Sol Sherry Distinguished Lecturer in Thrombosis: Thrombotic Stroke: Neuroprotective Therapy by Recombinant-Activated Protein C.Clinical features and underlying causes of cerebral venous thrombosis in Japanese patients.Occupancy of human EPCR by protein C induces β-arrestin-2 biased PAR1 signaling by both APC and thrombin.Neurotoxicity of the anticoagulant-selective E149A-activated protein C variant after focal ischemic stroke in mice.Endothelial microparticles released by activated protein C protect beta cells through EPCR/PAR1 and annexin A1/FPR2 pathways in islets.Early coagulation disorder after allogeneic stem cell transplantation is a strong prognostic factor for transplantation-related mortality, and intervention with recombinant human thrombomodulin improves the outcome: a single-center experience.Amyloid β suppresses protein C activation through inhibition of the endothelial protein C receptor (EPCR).Functional characterization of CXCR4 in mediating the expression of protein C system in experimental ulcerative colitis.Purpura fulminans in congenital protein C deficiency successfully treated with fresh frozen plasma and thrombomodulin.Protein C receptor stimulates multiple signaling pathways in breast cancer cells.Acute Anorectal Thrombophlebitis Caused by a Protein C Deficiency.Dual Anticoagulant and Antiplatelet Therapy for Coronary Artery Disease and Peripheral Artery Disease Patients.Anti-inflammatory effects of activated protein C on human dendritic cells.Failure to replicate thrombomodulin genetic variant predictors of venous thromboembolism in African Americans.Minor Plasma Lipids Modulate Clotting Factor Activities and May Affect Thrombosis Risk.Plasma protein S residues 37-50 mediate its binding to factor Va and inhibition of blood coagulation.Protein S K196E mutation reduces its cofactor activity for APC but not for TFPI
P2860
Q26781779-8E3EDD90-E59B-4096-A849-39F0EA4FFEB5Q30275531-D8A8C971-FEBB-4167-8595-318376BDAF83Q30457536-77421044-CCA1-41BC-B535-DD3618159154Q33766589-904531B3-3423-4521-A3F2-2D6E9AD4B8D5Q34209350-8EF6D6F8-FEA8-4C6A-ADA2-19FEBD7E38D9Q35694527-74E66B4A-01E5-488F-8088-DC96E6F8B24DQ35805622-3EA9F38B-991F-415A-9807-3B2DB2ACF04FQ36253998-627C06FC-A520-4E52-90B4-121B2CB06016Q36336828-9CF28FD1-990E-4F2D-B124-39BCDC5CBB27Q36535153-A560898B-B9A4-4FDA-8723-DEC3D3BC04F7Q36997361-0E2B060D-DD8A-4DCB-A90D-E21CF0C5649AQ37000469-DF34F453-72E2-48D2-964B-C25EDB0A5A4CQ37085780-027B9307-3554-4AF6-B18A-A35AE764616FQ37319913-AF247CCA-72B9-4E9E-896E-F4E59AD35CB7Q38126264-DD7BDFE1-A8C1-4ADE-95F3-4E035A7BE368Q38271832-3AFDCC17-7014-4F6E-94E6-3AC622C73053Q38640508-F9F3AF8F-F3F9-48EE-8059-DC050AEBAF87Q38663583-EC3E82C0-D6E0-40A1-995F-0643BAC30C35Q38985138-233F355D-7C30-4F93-81FC-56D696051EA0Q40175581-40518305-DA2D-44AE-B5A7-878338A8CD04Q42146853-F90FA3D3-EEBB-439A-ADF1-7272D43C4E68Q42929508-EF9C0BCB-542D-48E7-8B6A-770286998F8AQ43707258-21045672-44A7-41C9-94A5-FC2E59D30D6DQ44696198-2E0EAA5E-599D-4ACA-B0AE-52814294C5D7Q46341431-1664E10B-B208-41EE-80D7-840216E3B02BQ47151148-1C75B655-1BFC-48FC-9D4A-ADF181142DB4Q47266924-3E019F4D-B593-4675-8069-8DC2780D8A46Q47317600-B208EC1F-695D-4DA8-86AA-838B95A4D0B9Q47650808-7EC20745-9FF4-4F34-8BEF-C76F5AED57C8Q49960669-A8B7C788-ABD3-4824-B767-864C52F37938Q52950237-21370629-BC87-4B0C-86CC-B641F9A50293Q53727531-E6593078-42DD-4BDC-86AB-D4ABE7C28B29Q55359034-06F2D82E-4C64-44CE-9DFF-766C4F8AD9FEQ55454996-19D2A40E-AFB8-4137-9920-6F4423BF5E4EQ57821577-4D04D3F9-1057-450A-8D33-7E6350D93151
P2860
description
2012 nî lūn-bûn
@nan
2012 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Protein C anticoagulant and cytoprotective pathways
@ast
Protein C anticoagulant and cytoprotective pathways
@en
Protein C anticoagulant and cytoprotective pathways
@nl
type
label
Protein C anticoagulant and cytoprotective pathways
@ast
Protein C anticoagulant and cytoprotective pathways
@en
Protein C anticoagulant and cytoprotective pathways
@nl
prefLabel
Protein C anticoagulant and cytoprotective pathways
@ast
Protein C anticoagulant and cytoprotective pathways
@en
Protein C anticoagulant and cytoprotective pathways
@nl
P2093
P2860
P1476
Protein C anticoagulant and cytoprotective pathways
@en
P2093
Berislav V. Zlokovic
John H. Griffin
Laurent O. Mosnier
P2860
P2888
P304
P356
10.1007/S12185-012-1059-0
P407
P577
2012-04-01T00:00:00Z
P5875
P6179
1006650230